MedTrace Logo

A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis

NCT00293826 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 813

Last updated 2010-03-05

No results posted yet for this study

Summary

The purpose of this study is to determine if AMG 108 in combination with methotrexate is safe and effective in the treatment of rheumatoid arthritis.

Conditions

Interventions

DRUG

AMG 108

50mg via SC (subcutaneous) injection every 4 weeks

DRUG

AMG 108

250mg via SC (subcutaneous) injection every 4 weeks

DRUG

AMG 108

125mg via SC (subcutaneous) injection every 4 weeks

DRUG

Placebo

Placebo via SC (subcutaneous) injection every 4 weeks

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2007-11-30
Completion
2008-02-29

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293826 on ClinicalTrials.gov